Vadastuximab disitamab vedotin antibody-drug molecule representing a significant advancement in the management of acute myeloid leukemia (AML). This innovative therapy specifically targets CD33, a antigen frequently expressed on leukemic populations. The mechanism involves binding to CD33, causin

{Magrolimab | This innovative treatment represents a significant step in malignant immunotherapy due to its unique process of action .{ It | This approach blocks this “don’t eat me” signal, facilitated by a CD-47 surface marker – this essential driver of phagocytosis – enabling immune components